Reader TTS

As yet, no clear strategy has been developed for discontinuation of disease-modifying therapy in multiple sclerosis. A recent observational study adds new information, but the most

informative patient groups are still to be assessed comprehensively, and several questions need to be addressed in prospective studies. Access through your institution Buy or subscribe This

is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00

per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated

during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Freedman, M. S. _ et al_. Moving toward

earlier treatment of multiple sclerosis: findings from a decade of clinical trials and implications for clinical practice. _Mult. Scler. Relat. Disord._ 3, 147–155 (2014). Article  Google

Scholar  * Bsteh, G. _ et al_. Discontinuation of disease-modifying therapies in multiple sclerosis — clinical outcome and prognostic factors. _Mult. Scler._

http://dx.doi.org/10.1177/1352458516675751 (2016). * Tobin, W. O. & Weinshenker, B. G. Stopping immunomodulatory medications in MS: frequency, reasons and consequences. _Mult. Scler.

Relat. Disord._ 4, 437–443 (2015). Article  CAS  Google Scholar  * Kister, I. _ et al_. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity

score-matched study. _J. Neurol. Neurosurg. Psychiatry_ 87, 1133–1137 (2016). Article  Google Scholar  * Vellinga, M. M., Castelijns, J. A., Barkhof, F., Uitdehaag, B. M. & Polman, C. H.

Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. _Neurology_ 70, 1150–1151 (2008). Article  CAS  Google Scholar  * Hatcher, S. E., Waubant, E.,

Nourbakhsh, B., Cravtree-Hartman, E. & Graves, J. S. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. _JAMA Neurol._ 73, 790–794 (2016).

Article  Google Scholar  * Kappos, L. & European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in

treatment of secondary progressive multiple sclerosis. _Lancet_ 352, 1491–1497 (1998). Article  CAS  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Mark S.

Freedman is at the Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, Ontario, K1H 8L6, Canada., Mark S. Freedman Authors * Mark S. Freedman View author publications You can also

search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Mark S. Freedman. ETHICS DECLARATIONS COMPETING INTERESTS The author declares no competing financial

interests. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Freedman, M. Is there a safe time to discontinue therapy in MS?. _Nat Rev Neurol_ 13, 10–11

(2017). https://doi.org/10.1038/nrneurol.2016.192 Download citation * Published: 28 December 2016 * Issue Date: January 2017 * DOI: https://doi.org/10.1038/nrneurol.2016.192 SHARE THIS

ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard

Provided by the Springer Nature SharedIt content-sharing initiative